A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

Key Inclusion Criteria:

• Diagnosed with Sjögren's syndrome (SS) by meeting the 2016 American College ofRheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR)Classification Criteria.

• Have an European Alliance of Associations for Rheumatology Sjögren's SyndromeDisease Activity Index (ESSDAI) score of >= 5 despite symptomatic or local therapyat screening.

• Positive for either anti-Ro autoantibodies or rheumatoid factor (RF), or both atscreening (as per the central laboratory test).

Key Exclusion Criteria:

• Medical history of confirmed deep vein thrombosis, pulmonary embolism, or arterialthromboembolism within 2 years of screening.

• Active malignancy or history of malignancy within the last 5 years, except in situcarcinoma of cervix treated with apparent success with curative therapy > 12 monthsprior to screening OR cutaneous basal cell carcinoma following presumed curativetherapy.

• Individuals with any severe or life-threatening cardiovascular (includingvasculitis), respiratory, endocrine, gastrointestinal, hematological, psychiatric,or systemic disorder or any other condition that would place the individual atunacceptable risk of complications, interfere with evaluation of the IP, or confoundthe interpretation of participant safety or study results.

• Individuals who have a positive test for hepatitis B, hepatitis C, or HIV infection.A positive test for hepatitis B at screening is defined as: (1) positive for HBsAgOR (2) positive for either HBcAb or HBsAb and HBV DNA detected above the LLOQ byreflex testing by the central laboratory at screening.

• Active TB or untreated (per local guidelines) latent TB

• Individuals with a history of more than one episode of herpes zoster and/or anyopportunistic infection in the last 12 months, and active infection requiringsystemic treatment at the time of screening or through randomization, or history ofmore than 2 infections requiring intravenous (IV) antibiotics within 12 months priorto screening.

• Individuals who have received a live (attenuated) vaccine within the 4 weeks priorto randomization or plan to receive a live vaccine during their participation in thestudy.

• Last administration of experimental or investigational biologic or oral agents < 6months prior to screening.

• Individuals who have had previous treatment with any biologic B-cell-depletingtherapy (eg, rituximab, ocrelizumab, inebilizumab, ofatumumab, or ianalumab) within 12 months or other B-cell-targeting therapy (eg, belimumab) < 3 months prior toscreening.